Navigation Links
Polaris Enrolls First Patient in Phase 2 Clinical Trial of ADI-PEG 20 for the Treatment of Malignant Mesothelioma
Date:3/18/2011

SAN DIEGO, March 18, 2011 /PRNewswire/ -- Polaris Group announced today the enrollment of the first patient in a Phase 2 clinical trial of ADI-PEG 20 (pegylated arginine deiminase), the company's novel enzyme-based treatment for malignant mesothelioma. This randomized trial, called "ADAM" (Arginine Deiminase And Mesothelioma), will evaluate the treatment efficacy of ADI-PEG 20 as a single agent compared to the best supportive care. The primary endpoint of the study is progression free survival.

Peter Szlosarek, M.D., Ph.D., of the Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, is the lead investigator of the study. "It is with great anticipation that the ADAM trial has opened at Barts and other cancer centers in the U.K., including hospitals in Belfast, Cambridge, Hull, Manchester and Southampton," said Dr. Szlosarek. "We are pleased to be joining Polaris Group in exploring the potential benefits of ADI-PEG 20 in treatment of different cancers."

Malignant mesothelioma is a cancer of the lungs that frequently occurs in people who have been exposed to asbestos. The disease is usually diagnosed two to three decades after prolonged exposure and when it has generally spread beyond the stage for successful surgical treatment.  The prognosis for patients with late stage malignant mesothelioma is poor with a median survival of less than one year.

Polaris Group scientists and colleagues have been investigating the metabolic enzyme argininosuccinate synthetase (ASS) and its presence or absence in relationship to growth of normal cells and tumor cells.  ASS is required for the production of arginine, an amino acid needed for growth and replication of cells. Normal cells have normal levels of ASS and can produce sufficient arginine for their own growth and survival. However, many types of tumor cells cannot make their own arginine due to a deficiency in ASS and, therefore, must obtain it from e
'/>"/>

SOURCE Polaris Group
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Polaris Group and The Ludwig Institute for Cancer Research Ltd Initiate Phase 2 Trial of Amino-Acid Degrading Enzyme, ADI-PEG 20, in Patients with Small Cell Lung Cancer
2. YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
3. YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab
4. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
5. MEDRAD Installs First Intego(TM) PET Infusion System
6. Pioneering IVF Technique Produces Region's First Pregnancy
7. Immtech Reports Fiscal First Quarter 2009 Results
8. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
9. Huifeng Bio-Pharmaceutical (HFGB) Reports over $5 Million in Gross Sales; Record Results for the First Half of 2008
10. China-Biotics, Inc. Reports First Quarter 2009 Financial Results
11. Video: CSL Behring Provides $1.2M Grant for Worlds First Study of Postpartum Women with VWD, Common Bleeding Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... KS (PRWEB) August 19, 2014 ... offer fast and cost-effective metabolite production from bioactive ... proprietary chemistry platform, the technology enables convenient and ... According to XenoTech’s Vice President of Commercial ... synthesis for assessing clinical risk can be measured ...
(Date:8/19/2014)... VANCOUVER , Aug. 19, 2014 /PRNewswire/ - iCo ... (OTCQX: ICOTF), today reported results of its Oral ... latent HIV reservoirs.  The study, conducted by ImmuneCarta®, ... in vitro effectiveness of Oral Amp ... remain present in individuals despite intensive treatment with ...
(Date:8/18/2014)... 18, 2014 BioElectronics Corporation (OTC ... medical devices said that its EVP Dr. ... CEOLIVE.TV as part of its Executive Interview ... available at http://ceolive.tv/bioelectronics-corp-otc-biel/biel-videos/2282-ceolive-tv-interview-bioelectronics-corp-otcqb-biel ... investors the unique advantages of BioElectronics patented ...
(Date:8/18/2014)... August 18, 2014 According ... Market, By Application (Municipal Wastewater Treatment and Industrial ... and Multi Tubular), By Configuration (Internal/Submerged and External/Sidestream), ... by MarketsandMarkets, The market for membrane bioreactor systems ... growing at a CAGR of 15.28% between 2014 ...
Breaking Biology Technology:Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3
... 2011 The 10th annual Evergreen Healthcare Foundation Gala ... and friends of the hospital together at King County,s ... million to kick off a capital campaign that will ... imaging technology.   The "Evening in Paris" ...
... At this year,s American Academy of AntiAging (A4M) conference, ... leading factors in premature aging and disease. AGEs are dangerous ... sugar that attaches to a protein or lipid without the ... completely irreversible—and cause accelerated damage to the tissues and cells. ...
... /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA ), ... it will release its unaudited financial results for the first ... 13, 2011.  The Company will host a conference call on ... 2011 at 8:00 pm China Standard Time) to review the ...
Cached Biology Technology:Evergreen Foundation Gala Raises $1.16 Million for Cancer Care, Kicks off Capital Campaign 2At This Year's American Academy of AntiAging (A4M) Conference, Glycation and AGEs (Advanced Glycation End Products) Were Named the Leading Factors in Premature Aging and Disease 2Sinovac to Host Conference Call to Report First Quarter 2011 Unaudited Financial Results 2
(Date:8/19/2014)... many parts of the world, leprosy and tuberculosis ... cases of leprosy per year, with nearly all ... currently available century-old vaccine Bacille Calmette-Guerin, or BCG, ... leprosy, so a more potent vaccine is needed ... found a stronger weapon against both diseases., In ...
(Date:8/19/2014)... with neonatal abstinence syndrome (NAS) secondary to in-utero ... through withdrawal than others, but the underlying reasons ... (when genes are turned on or off) changes ... at Boston University School of Medicine (BUSM) and ... its kind study to identify some of these ...
(Date:8/19/2014)... Science Center at San Antonio and The University of ... of more than $750,000 in grants through the San ... in 2003, SALSI is a model of how a ... center join forces for greater research and graduate education. ... focus on public health issues and diseases of global ...
Breaking Biology News(10 mins):New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2San Antonio Life Sciences Institute awards $750,000 to innovators 2San Antonio Life Sciences Institute awards $750,000 to innovators 3
... Two chemicals -- trichloroethylene (TCE) and tetrachloroethylene (PCE) -- ... Base Camp Lejeune from the 1950s to 1985 have ... cancers. A new report from the National Research ... Potential Health Effects, reviews scientific evidence about the potential ...
... humans have evolved to naturally understand things like facial expressions ... found there is an ever-widening gap between what humans can ... successful adults in today,s modern society. Schools have traditionally helped ... the U.S. more may need to be done. "Schools ...
... Australian company Stadvis Pty Ltd have signed a worldwide ... predicts glycemic index (GI) and resistant starch (RS) in ... with an accurate means of testing the functional properties ... is much quicker and more cost-effective than the current ...
Cached Biology News:MU study finds connection between evolution, classroom learning 2CSIRO deal to commercialize 'artificial gut' 2
Immunochemistry 1 & 2...
... A.P. Johnstone and M.W. Turner ... strategies and methods used in the ... of antibodies in immunoassays, the standardisation ... ELISA techniques including amplification systems, enzyme ...
Supplemental reagent for annexin V assay....
See product name for description....
Biology Products: